LEO Pharma

LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare.

We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital.

Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. Together, we reach far beyond the skin. Disclaimer: This site is intended for discussions about LEO Pharma and the various initiatives LEO Pharma is involved in.

Due to regulations, discussions about pharmaceutical products are not allowed on this site. All content must be factual and non-promotional.